Cargando…
Identifying enriched drug fragments as possible candidates for metabolic engineering
BACKGROUND: Fragment-based approaches have now become an important component of the drug discovery process. At the same time, pharmaceutical chemists are more often turning to the natural world and its extremely large and diverse collection of natural compounds to discover new leads that can potenti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980782/ https://www.ncbi.nlm.nih.gov/pubmed/27510651 http://dx.doi.org/10.1186/s12920-016-0205-6 |
_version_ | 1782447514705723392 |
---|---|
author | Sharma, Sunandini Karri, Kritika Thapa, Ishwor Bastola, Dhundy Ghersi, Dario |
author_facet | Sharma, Sunandini Karri, Kritika Thapa, Ishwor Bastola, Dhundy Ghersi, Dario |
author_sort | Sharma, Sunandini |
collection | PubMed |
description | BACKGROUND: Fragment-based approaches have now become an important component of the drug discovery process. At the same time, pharmaceutical chemists are more often turning to the natural world and its extremely large and diverse collection of natural compounds to discover new leads that can potentially be turned into drugs. In this study we introduce and discuss a computational pipeline to automatically extract statistically overrepresented chemical fragments in therapeutic classes, and search for similar fragments in a large database of natural products. By systematically identifying enriched fragments in therapeutic groups, we are able to extract and focus on few fragments that are likely to be active or structurally important. RESULTS: We show that several therapeutic classes (including antibacterial, antineoplastic, and drugs active on the cardiovascular system, among others) have enriched fragments that are also found in many natural compounds. Further, our method is able to detect fragments shared by a drug and a natural product even when the global similarity between the two molecules is generally low. CONCLUSIONS: A further development of this computational pipeline is to help predict putative therapeutic activities of natural compounds, and to help identify novel leads for drug discovery. |
format | Online Article Text |
id | pubmed-4980782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49807822016-08-19 Identifying enriched drug fragments as possible candidates for metabolic engineering Sharma, Sunandini Karri, Kritika Thapa, Ishwor Bastola, Dhundy Ghersi, Dario BMC Med Genomics Research BACKGROUND: Fragment-based approaches have now become an important component of the drug discovery process. At the same time, pharmaceutical chemists are more often turning to the natural world and its extremely large and diverse collection of natural compounds to discover new leads that can potentially be turned into drugs. In this study we introduce and discuss a computational pipeline to automatically extract statistically overrepresented chemical fragments in therapeutic classes, and search for similar fragments in a large database of natural products. By systematically identifying enriched fragments in therapeutic groups, we are able to extract and focus on few fragments that are likely to be active or structurally important. RESULTS: We show that several therapeutic classes (including antibacterial, antineoplastic, and drugs active on the cardiovascular system, among others) have enriched fragments that are also found in many natural compounds. Further, our method is able to detect fragments shared by a drug and a natural product even when the global similarity between the two molecules is generally low. CONCLUSIONS: A further development of this computational pipeline is to help predict putative therapeutic activities of natural compounds, and to help identify novel leads for drug discovery. BioMed Central 2016-08-10 /pmc/articles/PMC4980782/ /pubmed/27510651 http://dx.doi.org/10.1186/s12920-016-0205-6 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sharma, Sunandini Karri, Kritika Thapa, Ishwor Bastola, Dhundy Ghersi, Dario Identifying enriched drug fragments as possible candidates for metabolic engineering |
title | Identifying enriched drug fragments as possible candidates for metabolic engineering |
title_full | Identifying enriched drug fragments as possible candidates for metabolic engineering |
title_fullStr | Identifying enriched drug fragments as possible candidates for metabolic engineering |
title_full_unstemmed | Identifying enriched drug fragments as possible candidates for metabolic engineering |
title_short | Identifying enriched drug fragments as possible candidates for metabolic engineering |
title_sort | identifying enriched drug fragments as possible candidates for metabolic engineering |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980782/ https://www.ncbi.nlm.nih.gov/pubmed/27510651 http://dx.doi.org/10.1186/s12920-016-0205-6 |
work_keys_str_mv | AT sharmasunandini identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering AT karrikritika identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering AT thapaishwor identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering AT bastoladhundy identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering AT ghersidario identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering |